


Institutional Biosafety Committee (IBC) Zoom Meeting Minutes


25 August 2025 9:00-11:00am (Mountain Time)

Attendance:

Voting IBC Members:



Non-voting IBC Members/Guests:



I. Call to Order: 9:00am (Mountain Time)


II. Conflict of Interest:

- All present IBC members were reminded that no member of an IBC may be involved (except
 to provide information requested by the IBC) in the review of approval of a project in which
 he/she/they have been or expect(s) to have a conflict of interest—including financial interests,
 personal relationships, or involvement in the research. Any committee member with a conflict
 of interest shall abstain from the vote.
- III. Review and Approval of Previous Minutes: 28 July 2025

The minutes were reviewed and approved by the IBC.

Approved = 14 Opposed = 0 Abstained = 1 (LH)

- IV. IBC Administrative Business:
 - A. IBC Administrative Changes: None
 - **B. Protocol Closures:**



C. Protocol Transfers: None



Recombinant and/or Synthetic Nucleic Acid Molecules Research Applications Review:

During the review, the IBC assessed the containment levels in addition to the facilities, procedures, practices, training, and expertise of the laboratory personnel involved in recombinant and/or synthetic nucleic acid molecules research. Additionally, the IBC reviewed agent characteristics, types of manipulations planned, sources of the inserted nucleic acid sequences, the nature of the inserted nucleic acid sequences, and whether an attempt will be made to obtain expression of a foreign gene, and, if so, the protein that will be produced. The Principal Investigator must determine the applicable section(s) of the NIH Guidelines.

V. New Business:

A. Environmental Health and Safety Office Updates:

i. EC welcomed MW back from leave.

B. Biosafety Office Updates:

- BH informed the IBC of an event of a near miss, where an agent spilled inside a BSC. Spill was properly contained, and there was no exposure and no injuries occurred.
- ii. The IBC approved updates to the IBC policy document which will be accessible on the IB website once signatures from the co-chairs are received.

Approved = 14 Opposed = 0 Abstained = 0

VI. Clinical Trial (Human Gene Transfer) Amendments and Notices:

1. Moore, Katie - # 25-0039: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy or Active Juvenile Idiopathic Inflammatory Myopathy

VII. Clinical Trial (Human Gene Transfer) Protocol Reviews:

1. Griffith, Melissa - # 25-1323: A PHASE 1 STUDY EVALUATING THE SAFETY AND PRELIMINARY EFFICACY OF ALLO-329, A DUAL ANTI-CD19 / ANTI-CD70 ALLOGENEIC CAR T CELL PRODUCT IN AUTOIMMUNE DISEASE (RESOLUTION)

Biosafety level: BSL-2 with droplet precautions

NIH Section(s): III-C Approved = 15 Opposed = 0 Abstained = 0

The IBC protocol presented was approved with the recommendation to address minor administrative items including clarifying dosing timeline, administration locations, use of a biological safety cabinet and provision of its details, anticipated effects for potential exposure, application checkboxes, updating the dosage figure for accuracy, and providing a signed and date application.

*AL left the meeting at 9:15am. JH and CW left the meeting at 9:21am.

VIII. New Laboratory Protocol Reviews:

- # 1726: Hormone and Cytokine regulation of Breast Cancer Biosafety level: BSL-2, ABSL-1 NIH Section(s): III-D-1, III-D-2, III-D-4, III-F

Approved = 14Opposed = 0



Abstained = 0

The IBC protocol presented was approved with the recommendation for modifications required to address items including application checkboxes, indicating non-transgenic animal use, lentiviral vector use, and updating information regarding infectious agents.

- # 1742: Diet-immune interactions during steady-state and inflammation

Biosafety level: BSL-2, ABSL-1

NIH Section(s): III-D-4-a, III-E-3, III-F

Approved = 14Opposed = 0Abstained = 0

The IBC protocol presented was approved with the recommendation for modifications required to address items including updating research narrative details, updating application checkboxes, updating PPE checkboxes, and clarifying shipping details.

IX. **De Novo Laboratory Protocol Reviews:**

- # 1123: Neuromodulation of circuits Biosafety level: BSL-1, ABSL-1

NIH Section(s): III-E-1, III-F

Approved = 14Opposed = 0Abstained = 0

The IBC protocol presented was approved with the recommendation to address minor administrative items including updating the research narrative, adding rDNA procedures, and updating SA details.

- # 1401: Study of the structure and function of systems important in gene regulation in Eukaryotes using structural, biochemical and biophysical methods.

Biosafety level: BSL1-LS, BSL-2

NIH Section(s): III-D-1, III-D-2, III-D-6, III-E-1, III-F, Appendix K

Approved = 14Opposed = 0Abstained = 0

The IBC protocol presented was approved with the recommendation to address minor administrative items including removing outdated details within the research narrative.

X. **Significant Amendment Reviews for Laboratory Protocols:**

- # 1667: Cell culture for 3D engineered tissues

Biosafety level: BSL-2

NIH Section(s): III-D-1, III-D-2, III-F

Approved = 14Opposed = 0Abstained = 0

The IBC protocol presented was approved with the recommendation to address minor administrative items including adding details to the research narrative.

XI. Exempt Protocols - New/Renewal:

- # 1064: Investigations of Bone Marrow-Derived Adipocytes and Their Role in Health and Disease.

XII. **Exempt Protocol Amendments**

IBC Meeting Minutes Ver. 2 – Apr. 2025



1. - # 1247: Pathogenesis of Bacterial Infections

2. - # 1720: Research Workflow for patient derived esophageal and gastric in vitro organoid models

XIII. Additional Business:

 The IBC approved updating the Cayuse IBC protocol form to allow for optional submission of progress report information from laboratories.

Approved = 14 Opposed = 0 Abstained = 0

XIV. Next Meeting Scheduled: 22 September 2025, 9:00am (Mountain Time)

XV. Adjournment: 9:58am (Mountain Time)